Anmbreen Jamroze, Research Assistant Professor at Roswell Park, shared a post on LinkedIn:
“This study from Roswell Park Comprehensive Cancer Center leverages duration-defined, treatment-exposed neoadjuvant ADT cohorts to reveal immune changes that cannot be captured by cell line or murine models.
The data show that neoadjuvant ADT dynamically reshapes the tumor immune microenvironment, with a transient immune-active phase (~ 3–5 months of nADT) followed by immune suppression and spatial T-cell exclusion.
These findings have direct implications for clinical trial design, helping explain the limited success of immunotherapy in advanced prostate cancer, and identifying a potential window of opportunity during which checkpoint inhibitor therapy may be most effective.”
Other articles on OncoDaily.